BioNTech (BNTX) closed at $87.71 on Oct 16, 2026, down 2.8% on the day. The stock is down 11.1% over the past month, down 4.8% over three months, down 7.9% year to date and down 15.9% over the past year. It trades 29.3% below its 52-week high of $124.00 and 10.3% above its 52-week low of $79.52. The close sits below its 50-day moving average ($98.78) and below its 200-day moving average ($97.68).
NextPick tracks BNTX in its Biotech basket alongside VRTX, MRNA, REGN, BIIB and ALNY. As of Oct 16, 2026, the basket's money-flow score is -8 (neutral), and the basket is down 3.4% over five sessions. Over the past month BNTX ranks 11th of 17 basket members by price change.
No — the Oct 16, 2026 close of $87.71 is 10.2% below the 200-day average of $97.68.
BNTX closed 29.3% below its 52-week high of $124.00.
NextPick groups BNTX with VRTX, MRNA, REGN, BIIB and ALNY in its Biotech basket.
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
